In the ECLIPSE study (N=1048), patients were randomized to receive guselkumab 100mg at weeks 0, 4, and 12 followed by every 8-week dosing or secukinumab 300mg at ...

According to results from the ECLIPSE trial, treatment with guselkumab was found to be superior to secukinumab in adult patients with moderate-to-severe plaque psoriasis based on 90% or better ...

Guselkumab is comparable to interleukin-17A and subcutaneous TNF inhibitors for efficacy, ... such as the ECLIPSE trial evaluating guselkumab in psoriasis, ...

Long-term (week 100) outcomes were compared among patients randomly assigned to receive guselkumab every 4 weeks (n = 245; mean age, 45.9 years; 58% men) or 8 weeks (n = 248; ...

Clinical remission at week 12 — the primary endpoint — was achieved by 27.6% of all patients treated with guselkumab compared with 6.5% of patients on placebo (P < .001).“These results are ...

Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary ...

Learn about side effects, dosage, cost, and more of Tremfya (guselkumab), a prescription injection that treats psoriatic arthritis and plaque psoriasis.

Guselkumab Continues Winning Streak in Crohn's Disease — Dual-acting IL-23 inhibitor tops placebo, ustekinumab in phase III trials by Ed Susman , Contributing Writer, MedPage Today May 22, 2024 ...

Find out how to take Guselkumab(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 GRAVITI study of TREMFYA® (guselkumab), the first and only IL-23 inhibitor, demonstrating robust results in subcutaneous (SC ...